Objective-The objective of this study was to determine the effects and molecular mechanisms of eotaxin, a newly discovered chemokine (CCL11), on endothelial permeability in the human coronary artery endothelial cells (HCAECs). Methods and Results-Cells were treated with eotaxin, and the monolayer permeability was studied by using a costar transwell system with a Texas Red-labeled dextran tracer. Eotaxin significantly increased monolayer permeability in a concentration-dependent manner. In addition, eotaxin treatment significantly decreased the mRNA and protein levels of endothelial junction molecules including zonula occludens-1 (ZO-1), occludin, and claudin-1 in a concentrationdependent manner as determined by real-time RT-PCR and Western blot analysis, respectively. Increased oxidative stress was observed in eotaxin-treated HCAECs by analysis of cellular glutathione levels. Furthermore, eotaxin treatment substantially activated the phosphorylation of MAPK p38. HCAECs expressed CCR3. Consequently, antioxidants (ginkgolide B and MnTBAP), specific p38 inhibitor SB203580, and anti-CCR3 antibody effectively blocked the eotaxin-induced permeability increase in HCAECs. Eotaxin also increased the phosphorylation of Stat3 and nuclear translocation of NF-B in HCAECs. Conclusions-Eotaxin increases vascular permeability through CCR3, the downregulation of tight junction proteins, increase of oxidative stress, and activation of MAPK p38, Stat3, and NF-kB pathways in HCAECs. (Arterioscler
T he vascular endothelium forms a barrier between the circulation and the interstitium. Aberration of endothelial barrier function leads to an abnormal extravasation of blood components and accumulation of fluid in the extravascular space, resulting in organ dysfunction. This injurious process has been implicated in inflammation, 1 trauma, sepsis, ischemia-reperfusion, diabetes, atherosclerosis, 2 and tumor development and metastasis. 3, 4 The endothelial barrier function is predominantly maintained by the interendothelial junction structures including tight junctions, adherens junctions, and gap junctions. 5, 6 Tight junctions include transmembrane proteins such as occludin, claudin, and junctional adhesion (JAM) molecules. These transmembrane molecules are linked intracellularly to the cytoskeleton via zonula occludens (ZO-1, ZO-2, and ZO-3). Adherens junctions are mainly composed of cadherins and ␤-catenin and provide strong mechanical attachments between adjacent cells. Gap junctions are communication structures, which allow the passage of small molecular weight solutes between neighboring cells. Several inflammation cytokines such as tumor necrosis factor ␣ (TNF-␣) can significantly induce endothelial permeability by changing these junction structures. 7, 8 Eotaxin is a recently discovered chemokine (CCL11) characterized by its high chemotactic selectivity for eosinophils. 9, 10 The position of 4 cysteine residues in eotaxin places it in the C-C family of chemokines, along with other chemokines such as RANTES, MCP-3, and MIP-1 alpha. Human eotaxin is an 8.3-kDa protein containing 74 amino acid residues. Eotaxin signals through the CCR3 receptor. It is produced by IFN-gamma-stimulated endothelial cells and TNF-␣-activated monocytes. A growing body of evidence indicates that eotaxin may participate in the atherosclerotic process. For example, eotaxin levels were increased in human atherosclerotic plaques, indicating a potential role of the eotaxin in vascular inflammation. 11 Circulating eotaxin levels were increased in patients with coronary artery disease, [12] [13] [14] and the presence of the nonconservative polymorphism in the eotaxin gene is associated with an increased risk for myocardial infarction. 15 Also, eotaxin is involved in endothelial inflammation 16 and vascular smooth muscle cell migration. 17 Vascular smooth muscle cells in human atheroma prominently express eotaxin suggesting that eotaxin may contribute to the progression of atherosclerosis. 11 These emerging studies indicate that eotaxin plays a crucial role in the cardiovas-cular system. However, the exact roles and mechanisms of eotaxin in the vascular system are largely unknown.
In the current study, we determined whether eotaxin could affect endothelial monolayer permeability. Human coronary artery endothelial cells (HCAECs) were treated with eotaxin, and monolayer permeability was investigated. In addition, potential molecular mechanisms such as the role of CCR3 receptors, endothelial junction molecules, oxidative stress, MAPK signal transduction, Stats, and NF-B transcription factors were also studied. These experiments, for the first time, explore the molecular mechanisms of eotaxin-induced endothelial dysfunction, thereby having clinical relevance and therapeutic potential.
Methods

Endothelial Permeability
HCAECs were obtained from Gelantis (San Diego, Calif) and cultured in HCAEC Growth medium (Gelantis). Human recombinant eotaxin was obtained from Peprotech (Rocky Hill, NJ). Paracellular permeability was studied in a Coaster Transwell system as previously described. 18
Real-Time RT-PCR Analysis
HCAECs were treated with different concentrations of eotaxin (50, 100, and 200 ng/mL) for 24 hours. Total RNA extraction and cDNA reverse transcription were done as previously described. 19 Primers for VE-cadherin, ZO-1, claudin-1, occludin, and JAM-1 were described in our previous publication. 5,19 -21 
Western Blot Analysis
Equal amount of proteins (40 g) was loaded onto 10% SDS-PAGE, fractionated by electrophoresis, and transferred to nitrocellulose membranes (BioRad). Primary antibodies against ZO-1, claudin-1, occludin, JAM-1, VE cadherin, CCR3, p38, NF-B p65, Stat3, and ␤-actin were used.
Cellular Glutathione Assay
HCAECs were treated with either eotaxin (100 ng/mL) or pretreated with MnTBAP (2 mol/L) for 30 minutes followed by eotaxin treatment for 45 minutes. Antimycin A (10 g/mL) and TNF-␣ (2 ng/mL) were used for the positive controls. Cellular glutathione (GSH) was measured as per manufacturer's instructions by following a GSH-Glo Glutathione assay kit (Promega).
Statistical Analysis
Data were expressed as the meanϮSD. Comparisons were made using the Student t test. A probability value Ͻ0.05 was considered statistically significant.
Supplemental Materials
Supplemental materials include the background information about gap junction, detail Materials and Methods, and 4 supplemental figures (available online at http://atvb.ahajournals.org).
Results
Eotaxin Increases Endothelial Monolayer Permeability in HCAECs
To determine whether eotaxin could affect the paracellular permeability of the endothelial cell monolayer, HCAECs were treated with eotaxin in a concentration-dependent manner, and endothelial permeability was analyzed by a Costar transwell system with a Texas Red-labeled dextran tracer. Treatment of HCAEC monolayer with increasing concentra-tions (100 and 200 ng/mL) of eotaxin for 24 hours significantly increased endothelial permeability by 43% and 59%, respectively, compared with untreated cells (nϭ3, PϽ0.05, Figure 1A ). TNF-␣ (2 ng/mL) was used as a positive control because it can significantly increase monolayer permeability. 18 Heat inactivated eotaxin did not increase the permeability through HCAECs indicating that the eotaxin effect is specific ( Figure 1B) . Interestingly, eotaxin-induced permeability increase in HCAECs was significantly blocked by the treatment with antioxidant ginkgolide B ( Figure 1A ). As a positive control, antimycin A (ROS generator) also increased endothelial permeability and this effect was effectively blocked by MnTBAP (cell permeable SOD mimetic; nϭ3, PϽ0.05, Figure 1C ). Similar to HCAECs, eotaxin treatment also increased the paracellular permeability in human umbilical vein endothelial cells (HUVECs) in a concentrationdependent manner (supplemental Figure I) . Eotaxin treatment (100 ng/mL) for 24 hours did not induce apoptosis when compared to untreated cells in HCAECs (supplemental Figure II ).
CCR3 Receptors Are Involved in Eotaxin-Induced Endothelial Permeability Increase
CC chemokines such as eotaxin act predominantly via the CCR3 receptors, members of the family of G proteincoupled receptors. Experiments were designed to determine whether CCR3 receptors are expressed on HCAECs and whether CCR3 receptors are involved in the effects of eotaxin on HCAECs. Western blotting analysis showed that CCR3 receptors were expressed in HCAECs, and eotaxin treatment did not change CCR3 receptor expression levels compared with untreated cells ( Figure 1D ). To further determine the involvement of CCR3 receptors in eotaxin-mediated hyperpermeability, HCAECs were pretreated with anti-CCR3 antibody for 30 minutes followed by eotaxin treatment for another 24 hours. Interestingly, anti-CCR3 antibody effectively reduced the basal endothelial permeability and eotaxininduced permeability increase in HCAECs (nϭ3, PϽ0.05, Figure 1B ). Immunohistological analysis showed that CCR3 was detected in human atherosclerotic arteries (supplemental Figure III) . These data demonstrate that CCR3 receptors play an important role in eotaxin-mediated endothelial permeability.
Eotaxin Decreases the Expression of Endothelial Tight Junction Proteins ZO-1, Claudin-1, and Occludin in HCAECs
To determine whether eotaxin could affect the expression of endothelial junction molecules, especially the tight junction proteins at both mRNA and protein levels, HCAECs were treated with eotaxin for 24 hours. Eotaxin treatment decreased the expression of tight junction proteins in a concentration-dependent manner. At 50, 100, and 200 ng/mL of eotaxin, ZO-1 mRNA was decreased by 8%, 25% (PϽ0.05), and 39% (PϽ0.05), respectively, compared with the control (nϭ3, Figure 2A ); occludin mRNA was decreased by 19% (PϽ0.05), 33% (PϽ0.05), and 55% (PϽ0.05), respectively; and claudin-1 mRNA was decreased by 5%, 45% (PϽ0.05), and 48% (PϽ0.05), respectively, compared with the control. There were no significant differences of VE
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cadherin and JAM-1 mRNA levels after eotaxin treatment compared with the control. Western blot analysis showed a parallel decrease in the protein levels of ZO-1, occludin, and claudin-1 in HCAECs when treated with eotaxin (100 ng/mL) compared with the control ( Figure 2B ). The commonly used antioxidant MnTBAP (2 mol/L), a cell permeable SOD mimetic, effectively blocked the eotaxin-induced decrease these molecules at the protein level. Consistent with the mRNA expression data, protein levels of VE cadherin and JAM-1 did not show any significant differences after eotaxin treatment ( Figure 2B ). To further confirm protein levels of tight junction proteins, flow cytometry analysis was used and the results showed that eotaxin treatment substantially decreased the protein levels of ZO-1, occludin and claudin-1 in HCAECs ( Figure 2C ). We also performed a time course study of the expression of tight junction molecules ZO-1, occludin, and claudin-1 in HCAECs. HCAECs were treated with eotaxin (100 ng/mL) and the mRNA levels of ZO-1, occludin, and claudin-1 were determined at different time points (0, 45 minutes, 2 hours, 6 hours, 18 hours, and 24 hours, respectively) by real-time PCR. Results showed that mRNA levels of these tight junction molecules were significantly decreased by more than 40% at or after 2 hours of eotaxin treatment compared with untreated controls (nϭ3, PϽ0.05, Figure 3 ).
Eotaxin Increases ROS Production in HCAECs
To determine whether oxidative stress could be involved in the action of eotaxin, ROS levels were analyzed by GSH assay. Superoxide can be converted to H 2 O 2 by superoxide dismutase (SOD), and then H 2 O 2 can be rapidly removed by catalase or peroxidases such as the GSH peroxidases, which use reduced GSH as the electron donor. Thus, cellular GSH levels are negatively correlated to ROS levels. Eotaxin (100 ng/mL) treatment of HCAECs for 45 minutes significantly reduced cellular GSH levels (nϭ3, PϽ0.05, Figure 4 ), whereas MnTBAP effectively blocked eotaxin-induced reduction in GSH levels in HCAECs. Two positive controls (antimycin A and TNF-␣) also significantly reduced cellular GSH levels in HCAECs (nϭ3, PϽ0.05, Figure 4 ), whereas MnTBAP partially blocked the effect of antimycin A. These data demonstrate that eotaxin increases oxidative stress in HCAECs.
Activation of p38, Stat3, and NF-B Is Involved in the Eotaxin-Induced Permeability Increase in HCAECs
To determine the signal transduction pathways involved in the action of eotaxin on HCAECs, the activation status of MAPK p38 was investigated using Western blot analysis because p38 is sensitive to oxidative stress. Treatment with eotaxin (100 ng/ mL) substantially increased the phosphorylation of p38 at 45 minutes of the treatment ( Figure 5A ), but not at 120 minutes (supplemental Figure IV) . Antimycin A treatment showed similar effects as to those of eotaxin on p38 phosphorylation, whereas the antioxidant MnTBAP effectively blocked eotaxinor antimycin A-induced p38 phosphorylation ( Figure 5A ). To determine the functional significance of p38 activation, cells were pretreated with specific p38 inhibitor SB203580 followed by eotaxin treatment for 24 hours and the monolayer permeabil- ity was analyzed using the Costar transwell system. Indeed, the specific p38 inhibitor SB203580 (10 mol/L) completely blocked the eotaxin-induced permeability increase in HCAECs (nϭ3, PϽ0.05, Figure 5B ).
We further determined whether transcriptional factors such Stat3 and NF-B could be involved in the eotaxin-induced signal as pathways because these transcriptional factors are also sensitive to oxidative stress. Eotaxin or antimycin A treatment for 45 minutes substantially increased the phosphorylation of Stat3 and nuclear translocation of NF-B in HCAECs, whereas antioxidant the MnTBAP effectively blocked these effects ( Figure 5A ). Thus, MAPK p38 and the transcriptional factors Stat3 and NF-B may be involved in the eotaxin-induced signal transduction pathways through the oxidative stress mechanism.
Discussion
Eotaxin (CCL11) is an eosinophil-specific chemo attractant which has been found to be highly expressed at sites of vascular pathology. 13 Eotaxin selectively attracts eosinophils by activating CCR3 receptors. 22 However, it is not clear whether eotaxin could contribute to the progression of atherosclerosis. The present study, for the first time, reports 3 novel findings: (1) eotaxin increases the paracellular permeability in HCAECs; (2) eotaxin decreases the expression of tight junction proteins involved in the regulation of endothelial barrier functions; and (3) eotaxin may mediate its effects through oxidative stress and activation of the p38 MAPK, Stat3, and NF-B signaling pathways.
In this study, we used a Costar transwell permeability model system to study the effect of eotaxin on paracellular permeability in HCAECs. This model has been used successfully in this laboratory to analyze the effects of ritanovir, 20 lysophosphatidylcholine, 21 stanniocalcin-1, 17 and secretoneurin 19 on endothelial permeability in vitro. We selected eotaxin concentrations ranging from 50 to 200 ng/mL based on the plasma eotaxin levels in patients with coronary artery disease. 22 Our results show that eotaxin treatment for 24 hours significantly increased endothelial permeability in HCAECs in a concentration-dependent manner. To rule out the possibility that the permeability increase is not attributable to the leakage through confluent HCAECs, the cell monolayer was grown to confluence, stained with Calcein AM, and checked under a fluorescent microscope to make sure that the monolayer was confluent (data not shown). Heat-inactivated (HI) eotaxin did not show any effects on endothelial permeability indicating its specific effect, but not potential contamination of endotoxin. The endothelial apoptotic cascade is an important underlying mechanism of capillary leakage. 23, 24 In this study, we have shown that eotaxin did not affect apoptosis of HCAECs in the experimental condition.
Chemokines and chemokine receptors have emerged as important factors involved in the mobilization and function of leukocytes. Chemokine receptors are expressed on a wide range of leukocytes, as well as on endothelial cells, neurons, and possibly other cell types where they are involved in signaling events that can lead to eosinophil and mast cell degranulation, T cell activation, lymphocyte homing, chemotaxis, and mitogenic effects as well as hematopoiesis. 25 In addition, overexpression of eotaxin and its receptor, CCR3, in human atherosclerosis have also been reported. 11 In our study, we found that the CCR3 receptor is constitutively expressed in HCAECs, whereas eotaxin treatment did not further increase the expression of CCR3 receptors. CCR3 expression was also observed in human atherosclerotic arter- Figure 4 . Effects of eotaxin, antimycin A, TNF-␣, and MnTBAP on the cellular glutathione (GSH) levels in HCAECs. Cells were treated with eotaxin (100 ng/mL), antimycin A (10 g/mL), TNF-␣ (2 ng/mL), or MnTBAP (2 mol/L) for 45 minutes. Cellular GSH levels were determined by a GSH-Glo Glutathione assay kit. nϭ3, *PϽ005 (the comparison is indicated by the arrow head). Error bars represent SD. Figure 5 . Effects of eotaxin, antimycin A, and MnTBAP on the activation of p38, Stat3, and NFB in HCAECs. A, Phosphorylation of p38 and Stat3 as well as nuclear translocation of NF-kB p65 in HCAECs. Cells were treated with either eotaxin (100 ng/mL) or antimycin A (10 g/mL) for 45 minutes or pretreated with MnTBAP (2 mol/L) for 30 minutes followed by antimycin A treatment for 30 minutes. Cytoplasmic and nuclear extracts were isolated, respectively. Phosphorylated (p) and total p38 and Stat3 as well as NF-B p65 proteins were detected by the Western blotting analysis. Loading efficiency was determined by reprobing the blot with ␤-actin antibody. The experiment was repeated twice. B, Endothelial permeability. HCAECs were treated with eotaxin (100 ng/mL) alone or pretreated with specific p38 inhibitor SB203580 followed by eotaxin treatment for 24 hours. Endothelial permeability was assayed. nϭ3, *PϽ0.05 (the comparison is indicated by the arrow head). Error bars represent SD.
ies. Pretreatment of HCAECs with anti-CCR3 antibody significantly reduced eotaxin-induced permeability increase. These findings suggest that CCR3 may play an important role in the eotaxin-mediated endothelial permeability increase in HCAECs.
Intercellular junctional structures mediate adhesion and communication between adjoining endothelial cells and comprise tight junction molecules including transmembrane proteins such as occludin, claudin, and JAM-1 and intracellular proteins such as ZO-1 and cingulin as well as adherens junction proteins including transmembrane protein VEcadherin and intracellular protein ␤-catenin. Tight junctions serve the major functional purpose of providing a "barrier" and a "fence" within the membrane by regulating paracellular permeability and maintaining cell polarity. In this study, we show that eotaxin significantly decreases the expression of tight junction proteins ZO-1, occludin, and claudin-1 in a concentration-dependent manner at both mRNA and protein levels. However, eotaxin does not decrease the expression of VE-cadherin and JAM-1. These data indicate that downregulation of tight junction proteins may be the key mechanism involved in the paracellular permeability increase in eotaxintreated HCAECs.
ROS including superoxide anion, hydrogen peroxide, hydroxyl radical, and peroxynitrite play critical roles in cardiovascular disease. 26 They could directly cause vascular damages, and could also act as signaling molecules for the gene expression in response to proinflammatory stimuli. [27] [28] [29] ROS cause endothelial barrier dysfunction through alterations in the cytoskeleton and extracellular matrix. 30 ROS are known to quench NO. 30 NO synthesis inhibition can potentiate agonist-induced increases in vascular permeability or increase basal microvascular permeability via an alteration of endothelial actin cytoskeleton. 31 In the present study, we showed a significant decrease of cellular GSH levels in eotaxin-treated cells, indicating that eotaxin may increase ROS production in HCAECs. Cotreatment of HCAECs with eotaxin and antioxidant MnTBAP substantially increased GSH levels, suggesting that MnTBAP may inhibit eotaxininduced oxidative stress in HCAECs. To further elucidate the role of ROS in eotaxin-mediated permeability increase, we treated the cells with antimycin A, an inhibitor of electron transport in mitochondria that has been used as a ROS generator in biological systems. We found that antimycin A can induce endothelial permeability and ROS production in HCAECs. To further confirm the involvement of ROS in eotaxin-mediated hyper-permeability, HCAECs were treated with either antioxidant ginkgolide B 32 or commonly used antioxidant MnTBAP, a cell-permeable SOD mimetic, which effectively blocked the eotaxin-induced increase in vascular permeability and decrease in the expression of tight junction proteins, respectively. The natural antioxidant gingo kolide B, a traditional Chinese herb from the plant Gingko Biloba, has less toxicity and side effects. Antioxidants are believed to counteract ROS and reduce the incidence of coronary artery disease. 33 Thus, the current study suggest that eotaxininduced oxidative stress may be one of the molecular mechanisms involved in the damage of endothelial barrier function, and the use of antioxidants could be a novel strategy in the treatment of patients with high incidence of cardiovascular disease.
MAPKs play an important role in mediating cellular functions in response to many extracellular stimuli. There are three important MAPKs including extracellular signal regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 in the cell. In the present study, we show that eotaxin can activate p38 in HCAECs. MAPK p38 activation was observed at 45 minutes of eotaxin treatment, and there was no activation of p38 at 2 hours after eotaxin treatment. We previously reported that quick activation of MAPK p38 (within 5 to 10 minutes) was observed during lysophosphatidylcholineinduced increase of monolayer cell permeability in HCAECs. 21 Sidestream cigarette smoke could also activate p38 within 60 minutes and induce an endothelial permeability increase in human pulmonary endothelial cells. 34 More importantly, the specific p38 inhibitor SB203580 effectively blocked eotaxininduced permeability increase in HCAECs. Blocking ROS generation also inhibited eotaxin-induced phosphorylation of p38, which indicates ROS acts as an upstream effector of p38 under the stimulation of eotaxin. Possibly transient expression of p38 initiates the events leading to dysregulation of barrier function through the activation of downstream signal transduction pathways. Indeed, IL-6 can increase endothelial permeability through activation of the transcription factor Stat3. 35 Activation of transcription factor NF-B has also been indicated for the TNF-␣-permeability increase in HCAECs. 18 We found activation of Stat3 and NF-B under the stimulation of eotaxin in HCAECs. It is possible that Stat3 and NF-B may regulate the expression of tight junction proteins. However, a direct link between Stat3 and NF-B activation and repression of tight junction proteins has not been determined in this study.
In summary, the present study demonstrates that eotaxin can increase vascular permeability in HCAECs. The underlying molecular mechanisms may involve downregulation of tight junction proteins, increase of oxidative stress, and activation of MAPK p38, Stat3, and NF-B. This study provides a new understanding of the biological functions of eotaxin on the vascular system. Reducing oxidative stress or inhibiting p38 activation may be a new strategy for inhibiting the detrimental effects of eotaxin on the vascular system, thereby preventing cardiovascular disease.
